68P Dynamic changes in neutrophil-to-lymphocyte ratio of head and neck cancer patients receiving nivolumab in a real-world setting

ConclusionBaseline and 12-wk NLR may allow to distinguish between long and short-term survivors. Improved response rates and survival in our series may be explained by the lower rate of platinum-refractory disease and the use of nivolumab in the first-line setting as well as beyond progression in a substantial proportion of patients. Treatment was well tolerated. These results merit confirmation in a larger sample.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureS. Cabezas-Camarero: Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research